Lorlatinib Reduces CNS Progression in ALK-Positive NSCLC
(MedPage Today) -- Patients with previously untreated advanced ALK-positive non-small-cell lung cancer (NSCLC) experienced better outcomes with first-line lorlatinib (Lorbrena) versus crizotinib (Xalkori), regardless of whether they had brain metastases...
Source: MedPage Today Hematology/Oncology - Category: Hematology Source Type: news
More News: Brain | Brain Cancers | Cancer | Cancer & Oncology | Hematology | Lung Cancer | Neurology | Non-Small Cell Lung Cancer